15.4.9 Combination Products
For combination products (mixtures), the names of the active ingredients should be provided. The proprietary name of the combination may be given in parentheses if necessary to clarify the product to which the article refers.
pseudoephedrine hydrochloride and triprolidine hydrochloride (Actifed)
povidone and hydroxyethylcellulose (Adsorbotear)
If the list of active ingredients is too long to use when referring to the combination product, the active ingredients should be listed at first mention and either an abbreviation or the proprietary name used thereafter.
The patient reported having taken several doses of Vanex HD, a liquid suspension of hydrocodone bitartrate, 10 mg, phenylephrine hydrochloride, 30 mg, and chlorpheniramine maleate, 12 mg, per 30 mL, the previous day.
The patient had been administered an artificial tear product containing 0.42% hydroxyethylcellulose and 1.67% povidone (Adsorbotear).
Only the active ingredients must be listed. However, in some circumstances it may be necessary to include all ingredients, including preservatives, if sensitivity to an ingredient may be important.
The patient had complained of red, itching eyes after using an artificial tear product containing hydroxyethylcellulose and povidone with edetate disodium and thimerosal as preservatives (Adsorbotear).
The USP may provide a pharmacy equivalent name (PEN)1(p13) to refer to a combination product, such as co-triamterzide for the combination of triamterene and hydrochlorothiazide. However, PEN terms are not official USP titles and should be used only if they are familiar and clear to readers. Because co-triamterzide is unlikely to be familiar to most readers, the following approach can be used:
Participants were given a capsule containing a combination of 25 mg of hydrochlorothiazide and 50 mg of triamterene each day at 8 am. Those not able to tolerate hydrochlorothiazide-triamterene were given 50 mg of metoprolol at 8 am.
Trimethoprim-sulfamethoxazole (80 mg of trimethoprim and 400 mg of sulfamethoxazole) administered once daily effectively prevented reinfection in 93% of patients.